Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"), together with its U.S. subsidiary Eisai Inc. and Arena Pharmaceuticals, Inc. announced today that the results from the two-year BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial with lorcaserin will be published in the July 15, 2010, issue of the New England Journal of Medicine. Lorcaserin is a novel obesity and weight management drug. Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc. has granted Eisai Inc... 
More...
More...